Navigation Links
China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
Date:8/29/2013

SHENZHEN, China, Aug. 29, 2013 /PRNewswire-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the second quarter ended June 30, 2013.

Financial HighlightsFor the quarter ended June 30, 2013:

  • Same store sales increased by 8.6% compared with the second quarter of 2012
  • Revenue increased to RMB638.8 million (US$104.1 million) compared with RMB617.6 million for second quarter 2012
  • Loss from operations was RMB1.0 million (US$0.2 million), compared with income from operations of RMB 3.9 million for the second quarter 2012.
  • Net cash-flow from operating activities was RMB14.6 million (US$2.4 million), compared to RMB30.2 million in second quarter 2012
  • Mr. Fuxiang Zhang, Chief Executive Officer of Nepstar, commented, "During the second quarter, we adopted a more proactive marketing strategy to propel growth in revenue and to improve our store productivity. As a result, our average daily store traffic increased by eleven visits and same store sales grew by 8.6%, with fewer operating stores compared with the second quarter of 2012. While this promotional strategy has impacted our near-term gross margin and profitability, we believe the longer-term benefit of increased store traffic and participation in our loyalty programs will provide sustainable growth in margin over time and will ultimately enhance our competitiveness."

    Second Quarter ResultsDuring the second quarter of 2013, the Company opened 25 new stores and closed 48 stores. As of June 30, 2013, the Company had 2,071 directly operated stores in total.  

    Revenue for the second quarter of 2013 increased by 3.4% to RMB638.8 million (US$104.1 million) from RMB617.6 million for the same period in 2012. Same store sales (for the 1,969 stores opened before December 31, 2011 and were still operating) for the second quarter of 2013 increased by 8.6% compared with the same period in 2012. The increase in same store sales was primarily due to promotional initiatives aimed at increasing store traffic.

    Second quarter revenue contribution by product category was 22.3% from prescription drugs; 38.2% from over-the-counter ("OTC") drugs; 14.8% from nutritional supplements; 4.0% from herbal products; and 20.7% from convenience and other products.

    Second quarter gross profit was RMB280.8 million (US$45.7 million), a slight decrease from RMB287.5 million for the same period in 2012. Gross margin in the second quarter of 2013 was 44.0% compared with 46.5% for the same period of 2012. This decrease in gross margin was primarily the result of a more proactive marketing strategy for promoting the convenience and other products category.

    The Company's portfolio of private label products was expanded to 2,069 types of products as of June 30, 2013. Sales of private label products represented approximately 25.0% of the Company's revenue and 33.8% of gross profit for the second quarter of 2013.

    Sales, marketing and other operating expenses, as a percentage of revenue, in the second quarter of 2013 decreased to 38.9% from 40.8% in the same period of 2012. This decrease was primarily due to growth in same store sales and closure of underperforming stores.  

    General and administrative expenses as a percentage of revenue in the current quarter was 4.6%, compared with 5.1% for the same period in 2012. This decrease was mainly due to the continued implementation of rigorous cost control measures.

    During the second quarter, we recognized impairment loss of RMB 3.4 million, which represents the reduction of the carrying amount of the property and equipment of certain underperforming stores.

    Loss from operations in the second quarter of 2013 was RMB1.0 million (US$0.2 million), compared with income from operations of RMB3.9 million in the same period in 2012. The loss from operations in the second quarter of 2013 was mainly due to lower gross margin and the impairment loss. Excluding the impairment charge, income from operations was RMB 2.3 million (US$0.4 million).

    Interest income for the second quarter of 2013 was RMB4.2 million (US$0.7 million) compared with RMB3.9 million in the same period in 2012.

    Dividend income from cost method investments was RMB0.4 million (US$0.1 million) in the second quarter of 2013, compared with RMB3.1 million in the same period of 2012. On December 28, 2012, the Company completed the sale of its entire 40% equity interests in Yunnan Jianzhijia Chain Drugstore Ltd. for a total cash consideration of approximately RMB 81.5 million. Equity in income of an equity method investee was nil in the second quarter of 2013, compared with a loss of RMB1.0 million in the same period in 2012.

    The Company's effective tax rate was 208.0% for the second quarter of 2013, compared with 74.9% for the same period in 2012. The Company's income tax expense was RMB 7.5 million for the second quarter of 2013, compared with RMB 7.4 million for the same period in 2012. The amounts of income tax expense were stable compared with the same period last year, and the higher effective rate for the current quarter was mainly due to the effect of operating losses from certain of our loss-making subsidiaries, for which full valuation allowances were made on their deferred tax assets.

    Net loss for the second quarter of 2013 was RMB3.9 million (US$0.6 million), which represented RMB0.04 (US$0.01) basic and diluted loss per ADS. Net income for the second quarter of 2012 was RMB2.5 million, which represented RMB0.02 basic and diluted earnings per ADS.

    Net cash-flow from operating activities in the second quarter of 2013 was RMB14.6 million (US$2.4 million), compared with RMB30.2 million for the same period in 2012.

    As of June 30, 2013, the Company's total cash, cash equivalents, bank deposits and restricted cash were RMB666.0 million (US$108.5 million) and its shareholders' equity was RMB1.03 billion (US$167.6 million). This compares with total cash, cash equivalents, bank deposits and restricted cash of RMB664.4 million and shareholders' equity of RMB1.03 billion as of December 31, 2012.

    Business Outlook"Going forward, our focus remains on optimization of our product mix and maintaining momentum in store traffic and sales to stabilize and regain growth in margin and profitability," Mr. Zhang concluded. "Looking to the second half of the year, we expect same store sales and also the daily store traffic growth to continue."

    Conference Call InformationThe Company will host a conference call and a simultaneous webcast, on Thursday, August 29, 2013 at 8:00 a.m. Eastern Time / 8:00 p.m. Beijing Time. Interested parties may participate in the conference call by dialing in approximately five minutes before the appointed starting time at +1-877-407-9210 (North America) or +1-201-689-8049 (International). A live web cast of the conference call will be available on the Company's website at http://www.nepstar.cn.

    A replay of the call will be available shortly after the conclusion of the conference call through September 5, 2013 at 11:59 p.m. Eastern Time. An archived web cast of the conference call will be available on the Company's website at http://www.nepstar.cn. Interested parties may access the replay by dialing +1-877-660-6853 (North America) or +1-201-612-7415 (International) and entering conference ID number 419160.

    About China Nepstar Chain Drugstore Ltd.China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is the largest retail drugstore chain in China based on the number of directly operated stores. As of June 30 2013, the Company had 2,071 stores across 75 cities, one headquarter distribution center and 16 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmaceutical products and services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the continuing economic growth in China and to take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn.

    Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    Exchange Rate InformationThe United States dollar (US$) amounts disclosed in this press release are presented solely for the convenience of the reader. Translations of amounts from RMB into United States dollars were calculated at the certified exchange rate of US$1.00 = RMB6.1374 on June 28, 2013 as set forth in the H.10 weekly statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted into US$ at that rate on June 28, 2013, or at any other date. The percentages stated are calculated based on RMB amounts.

    ContactsZixin Shao
    China Nepstar Chain Drugstore Ltd.
    Chief Financial Officer
    +86-755-2641-4065
    ir@nepstar.cn

    Dixon Chen
    Grayling
    Investor Relations
    +1-646-284-9403
    dixon.chen@grayling.com

    Ivette Almeida
    Grayling 
    Media Relations
    +1-646-284-9455
    ivette.almeida@grayling.com

    Tables followChina Nepstar Chain Drugstore Ltd. Unaudited Condensed Consolidated Statements of Comprehensive Income/(Loss)(amounts in thousands – except per-share and per-ADS data)Three-month period endedJune 30,201220132013RMBRMBUSDRevenue

    617,606

    638,758

    104,076Cost of goods sold

    (330,148)

    (358,000)

    (58,331)Gross profit

    287,458

    280,758

    45,745Sales, marketing and other operating expenses

    (252,289)

    (248,719)

    (40,525)General and administrative expenses

    (31,272)

    (29,698)

    (4,839)Impairment losses

    -

    (3,380)

    (551)Income/(loss) from operations

    3,897

    (1,039)

    (170)Interest income

    3,917

    4,218

    687Dividend income from cost method investments

    3,124

    436

    71Equity in income of an equity method investee

    (995)

    -

    -Income before income tax expense

    9,943

    3,615

    588Income tax expense

    (7,445)

    (7,520)

    (1,225)Net income/(loss)

    2,498

    (3,905)

    (637)Basic earnings/(losses) per ordinary share

    0.012

    (0.020)

    (0.003)Basic earnings/(losses) per ADS

    0.024

    (0.040)

    (0.006)Diluted earnings/(losses) per ordinary share

    0.012

    (0.020)

    (0.003)Diluted earnings/(losses) per ADS

    0.024

    (0.040)

    (0.006)Net income/(loss)

    2,498

    (3,905)

    (637)Other comprehensive loss, net of tax:Foreign currency translation adjustments

    (496)

    (512)

    (83)Comprehensive income/(loss)

    2,002

    (4,417)

    (720) China Nepstar Chain Drugstore Ltd.Unaudited Condensed Consolidated Balance Sheets(amounts in thousands) As ofAs ofAs ofDecember 31,June 30,June 30,201220132013RMBRMBUSDASSETSCurrent assetsCash and cash equivalents

    371,256357,54058,256Short-term bank time deposits

    237,100272,44044,390Restricted cash

    36,00036,0005,866Accounts receivable, net of allowance for doubtful
    accounts

    114,601114,72018,692Amounts due from related parties

    8,25410,7051,744Prepaid expenses, deposits and other current assets

    147,252161,00226,233Inventories

    478,483452,51473,731Deferred tax assets

    1,7042,450399Total current assets

    1,394,6501,407,371229,311Non-current assetsLong-term bank time deposits

    20,000--Property and equipment, net

    120,237114,64318,679Rental deposits

    38,23640,1016,534Cost method investments

    12,63812,6382,059Intangible assets, net

    2,8682,868467Goodwill

    51,81951,8198,443Deferred tax assets

    3,0567,5001,223Accrued interest income

    507--Total non-current assets

    249,361229,56937,405Total assets1,644,0111,636,940266,716LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilitiesAccounts payable

    356,095346,40156,441Bills payable

    20,53424,0633,921Amounts due to related parties

    18,38123,1993,780Accrued expenses and other payables

    105,503104,91417,094Income tax payable

    40,96729,8054,856Deferred income

    14,32717,3552,828Total current liabilities

    555,807545,73788,920Non-current liabilitiesDeferred income

    18,36517,1452,794Deferred tax liabilities

    7,4997,6951,254Other non-current liabilities

    36,23737,7006,142Total non-current liabilities

    62,10162,54010,190Total liabilities617,908608,27799,110Shareholders' equityShare capital

    15815826Additional paid-in capital

    832,811832,811135,694Accumulated other comprehensive loss

    (41,688)(42,337)(6,898)Retained earnings

    234,822238,03138,784Total shareholders' equity

    1,026,1031,028,663167,606Total liabilities and shareholders' equity1,644,0111,636,940266,716


    '/>"/>
    SOURCE China Nepstar Chain Drugstore Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
    2. CentraState and Freehold Radiology Group train physicians from China
    3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
    4. ResearchMoz: Global and China 4A Zeolite Industry 2012 Deep Research Report - Market Research Report
    5. China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
    6. China Biologic Products Reports Higher Results for the First Quarter 2012
    7. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
    8. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
    9. China Botanic Attends 67th PHARMCHINA Fair
    10. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
    11. China Botanic Attends the 111th China Import and Export Fair
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... Ind. , Feb. 5, 2016  Zimmer Biomet ... pricing of the previously announced underwritten secondary offering of ... its stockholders, consisting of affiliates of Blackstone and Goldman ... at an initial price of $96.45 per share. The ... the offering.  Neither Zimmer Biomet nor any of its ...
    (Date:2/5/2016)... Site Profile: --> ... Recognition People, announced their latest primary healthcare case study where speech ... times and to save the practice money. Site Profile: ... Challenge: --> ,- Wirral CCG ,- VoicePower client ... ,- Wirral CCG ,- VoicePower client since 2013 Challenge: ...
    (Date:2/4/2016)... , Feb. 4, 2016 For hospitals considering ... those already participating in the program, the Health Resources ... to as the , Mega-Guidance , could have significant ... is published in September 2016. Essential Insights ... Service Marketing , summarizes the Mega-Guidance,s key proposed changes, ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
    (Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
    (Date:2/5/2016)... Tennessee (PRWEB) , ... February 05, 2016 , ... ... Community College President George H. Van Allen have signed a joint enrollment and ... provides a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , ...
    (Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official operators of ... direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque ... , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to ...
    (Date:2/5/2016)... York (PRWEB) , ... February 05, 2016 , ... Regular ... and find themselves having to wait longer to access the treadmills. It’s a predictable ... Year’s resolutions to lose weight and get in shape by joining gyms, starting new ...
    Breaking Medicine News(10 mins):